Intellia Therapeutics, Inc.
(NASDAQ : NTLA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.09%178.001.3%$463.16m
CELGCelgene Corporation
0.98%97.461.3%$422.24m
GILDGilead Sciences, Inc.
1.25%67.190.9%$393.36m
BIIBBiogen Inc.
2.07%232.391.3%$354.74m
ILMNIllumina, Inc.
1.45%348.993.5%$271.83m
REGNRegeneron Pharmaceuticals, Inc.
2.48%312.802.6%$234.66m
AAgilent Technologies, Inc.
0.72%70.471.6%$213.59m
VRTXVertex Pharmaceuticals Incorporated
2.21%173.981.9%$198.48m
ARRYArray BioPharma Inc.
57.06%46.488.2%$186.21m
EXASExact Sciences Corporation
0.65%110.4925.3%$184.06m
ALXNAlexion Pharmaceuticals, Inc.
2.56%120.952.0%$176.57m
BMRNBioMarin Pharmaceutical Inc.
4.33%84.344.3%$136.47m
MRTXMirati Therapeutics Inc.
6.40%100.292.5%$113.86m
IONSIonis Pharmaceuticals, Inc.
4.09%64.638.2%$96.90m
INCYIncyte Corporation
5.16%81.722.5%$91.81m

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.